Research programme: lung cancer therapeutics - Belfer Center/Janssen Biotech
Alternative Names: Immuno-oncology therapeutics - Belfer Center/Janssen BiotechLatest Information Update: 28 Jul 2018
At a glance
- Originator Belfer Institute for Applied Cancer Science; Janssen Biotech
- Developer Belfer Center for Applied Cancer Science; Janssen Biotech
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Lung-cancer in USA
- 24 Jun 2014 Early research in Lung cancer in USA (unspecified route)